{
    "clinical_study": {
        "@rank": "97623", 
        "arm_group": [
            {
                "arm_group_label": "Bosutinib", 
                "arm_group_type": "Experimental", 
                "description": "Bosutinib, 400 mg, oral administration once a day"
            }, 
            {
                "arm_group_label": "Imatinib", 
                "arm_group_type": "Active Comparator", 
                "description": "Imatinib, 400 mg, oral administration once a day"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive\n      bosutinib or imatinib for the duration of the study."
        }, 
        "brief_title": "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be open for enrollment until the planned number of approximately 500\n      Philadelphia Chromosome Positive (Ph+) patients have been randomized (approximately 250 Ph+\n      patients in each treatment arm; a total of approximately 530 Ph+ and Ph- patients). All\n      patients will be treated and/or followed for 5 years (240 weeks) after randomization until\n      the study has closed. Patients who discontinue study therapy early due to disease\n      progression or intolerance to study medication will continue to be followed yearly for\n      survival for up to 5 years (240 weeks) after randomization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Molecular diagnosis of CP CML of \u2264 6 months (from initial diagnosis).\n\n          2. Adequate hepatic, renal and pancreatic function.\n\n          3. Age \u2265 18 years.\n\n        Exclusion Criteria:\n\n          1. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs),\n             with the exception of hydroxyurea and/or anagrelide treatment.\n\n          2. Any past or current Central Nervous System (CNS) involvement, including\n             leptomeningeal leukemia.\n\n          3. Extramedullary disease only.\n\n          4. Major surgery or radiotherapy within 14 days of randomization.\n\n          5. History of clinically significant or uncontrolled cardiac disease.\n\n          6. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic\n             hepatitis B (hepatitis B surface-antigen positive), hepatitis C or evidence of\n             decompensated liver disease or cirrhosis.\n\n          7. Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease,\n             Ulcerative Colitis, or prior total or partial gastrectomy.\n\n          8. History of another malignancy within 5 years with the exception of basal cell\n             carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered\n             adequately treated and currently in complete remission for at least l2 months.\n\n          9. Current, or recent (within 6 months), participation in other clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "530", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130557", 
            "org_study_id": "AV001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bosutinib", 
                "intervention_name": "Bosutinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Imatinib", 
                "intervention_name": "Imatinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Imatinib", 
                "Molecular Mechanisms of Pharmacological Action"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Leukemia", 
            "Myelogenous", 
            "Chronic", 
            "BCR-ABL Positive", 
            "Bosutinib", 
            "Leukemia, Myeloid", 
            "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
            "Philadelphia Chromosome", 
            "Neoplasms by Histologic Type", 
            "Bone Marrow Diseases", 
            "Hematologic Diseases", 
            "Translocation, Genetic", 
            "Pathologic Processes", 
            "Imatinib", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Molecular Mechanisms of Pharmacological Action"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Use central contact"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario"
                }, 
                "name": "Toronto, Ontario"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase (CP) Chronic Myelogenous Leukemia (CML)", 
        "overall_contact": {
            "email": "Avillion@avillionllp.com", 
            "last_name": "Dr. Laurence Reilly, MBChB LLM"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Brazil: National Health Surveillance Agency", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "Finland: Finnish Medicines Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Israel: Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Mexico: Ministry of Health", 
                "Norway: Norwegian Medicines Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Singapore: Health Sciences Authority", 
                "Slovakia: State Institute for Drug Control", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Sweden: Medical Products Agency", 
                "Taiwan : Food and Drug Administration", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MMR is defined as <0.1%Bcr-Abl1 on the International Scale (IS) by Real Time Quantitative Polymerase Chain Reaction (RT-PCR)", 
            "measure": "Compare proportion of participants with Major Molecular Response (MMR) at 12 Months in the bosutinib arm with that of the imatinib arm", 
            "safety_issue": "No", 
            "time_frame": "12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130557"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compare proportion of participants with MMR at 18 Months in the bosutinib treatment group with the imatinib treatment group", 
                "safety_issue": "No", 
                "time_frame": "18 Months"
            }, 
            {
                "description": "Duration of MMR is measured only for participants who initially respond to study medication.", 
                "measure": "To determine the duration of MMR in the bosutinib treatment group with the imatinib treatment group", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "CCyR is defined as absence of detectable Ph chromosomes in bone marrow aspirate", 
                "measure": "To determine the proportion of participants with Complete Cytogenetic Response (CCyR) by 12 Months in both treatment groups", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "Duration of response is measured only for participants who initially respond to study medication.", 
                "measure": "To determine the duration of CCyR in both treatment groups", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }
        ], 
        "source": "Avillion Development 1 Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avillion Development 1 Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}